盖茨和泛美卫生组织的目标是通过非专利药品和大宗采购,增加低收入国家获得减重药物的机会。 Gates and PAHO aim to boost access to weight-loss drugs in low-income nations via generics and bulk purchasing.

比尔·盖茨(Bill Gates)和泛美卫生组织(PAHO)正在努力扩大低收入国家中诸如韦戈维(Wegovy)和穆恩贾罗(Mounjaro)等减重药物的获取渠道,因为肥胖症和相关疾病正在上升。 Bill Gates and PAHO are working to expand access to weight-loss drugs like Wegovy and Mounjaro in lower-income countries, where obesity and related diseases are rising. 它们的目的是使治疗更加负担得起,利用印度和中国等国家即将到期的专利,使非专利生产成为可能。 They aim to make treatments more affordable, leveraging upcoming patent expirations in nations like India and China to enable generic production. 泛美卫生组织正在考虑利用其批量采购基金来降低成本并加快监管审批。 PAHO is considering using its bulk procurement fund to lower costs and speed up regulatory approval. 尽管尚未宣布具体的推出计划,但在世卫组织的支持下,这项努力回应了日益增长的全球卫生关切和预期的经济负担。 The effort responds to growing global health concerns and projected economic burdens, with support from the WHO, though no specific rollout plans have been announced.